CytomX医疗 CTMX 深 沪
等待开盘 09-19 09:30:00 美东时间
2.04
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.04
- 总市值 3.37亿
- 52周最高 3.095
- 市盈率 静 5.42
- 换手率 0.00%
- 52周最低 0.40
- 委 比 0.00%
- 总股本 1.65亿
- 历史最高 35.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.40
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多New York governor seeks federal help to speed up nuclear expansion
New York Governor Kathy Hochul is urging the federal government to speed up the approval process for new nuclear energy projects as the state confronts growing electricity demand, particularly from AI...
09-11 04:33
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics will present two oral abstracts at the ISRV/IMRP conference in Singapore, September 17-20, 2025. The late-breaking presentation, "NAVIGATE: Phase 2b Trial of CD388 for Influenza Prevention," by Dr. Rick Bright will discuss trial results on healthy adults. Additionally, Dr. Andreev Konstantin will present "Single Dose of CD388 Protects Against H5N1 in Ferret Model" in a parallel session. CD388, Cidara's lead DFC candidate, aims...
09-03 12:00
CytomX Therapeutics to Present at Upcoming September Investor Conferences
<p align="justify">CytomX Therapeutics announced that its management will participate in three investor conferences in September 2025: the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference, all held in New York City. Additionally, live webcasts of their presentations will be available on CytomX’s website, www.cytomx.com. The company focuses on...
08-28 12:00
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
08-22 16:35
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Celldex Therapeutics报告了其针对嗜酸性食管炎（EoE）的二期临床试验顶线结果。研究显示，其候选药物barzolvolimab显著减少了胃肠道中的肥大细胞，但并未改善临床症状，表明肥大细胞可能并非EoE的主要驱动因素。药物安全性良好。 Celldex将不会推进barzolvolimab在EoE中的开发，但将继续探索其在其他适应症中的潜力。公司将于今日举办网络研讨会讨论结果。
08-19 20:01
美股机会日报丨贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%
贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%；马斯克：特斯拉Robotaxi9月将向公众开放>>
08-13 21:03
期权扫描 | Meta创新高！期权成交激增172%；BBAI看涨期权涌入占比近63%
Meta创新高！期权成交激增172%至60万张；BBAI绩后重挫，看涨期权涌入占比近63%>>
08-13 14:02
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
CytomX Therapeutics has enrolled 73 colorectal cancer patients in their CTMX-2051-101 Phase 1 study, aiming to provide a data update in Q1 2026. The study remains active with patients continuing to receive CX-2051 across all expansion doses. A single Grade 5 treatment-related acute kidney injury occurred in a patient with a complex medical history, reported to the FDA. The Safety Review Committee supported continued study execution. CX-2051 is a ...
08-13 12:00
CytomX Therapeutics Q2 Sales $18.658M Beat $14.725M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly sales of $18.658 million which beat the analyst consensus estimate of $14.725 million by 26.71 percent. This is a 25.71 percent decrease over sales of $25.115 million
08-08 04:13
